氯卡色林

{{Drugbox
| verifiedrevid = 666742063
| drug_name =
| image = Lorcaserin.svg
| image_class = skin-invert-image
| width = 200px
| image2 = Lorcaserin ball-and-stick model.png
| image_class2 = bg-transparent
| width2 = 200px

| pronounce =
| tradename = Belviq
| Drugs.com =
| MedlinePlus = a613014
| licence_CA =
| licence_EU =
| DailyMedID = Lorcaserin
| licence_US = Lorcaserin
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_US = X
| pregnancy_US_comment =
| pregnancy_category=
| dependency_liability =
| addiction_liability =
| routes_of_administration = 口服
| class = 5-羟色胺2C受体激动剂
| ATCvet =
| ATC_prefix = A08
| ATC_suffix = AA11
| ATC_supplemental =

| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US = Schedule IV
| legal_US_comment = / 已撤市
| legal_UN =
| legal_UN_comment =
| legal_status =

| bioavailability =
| protein_bound = 70%
| metabolism = 大部分经肝脏它通过激活下丘脑中控制食欲的5-羟色胺2C受体来抑制食欲。

氯卡色林于2012年获批上市，在2020年因被发现增加使用者的患癌风险而在美国撤市。

参考资料
外部链接
*